

INVESTOR PRESENTATION AND UPDATE

Perth, Australia, 20 September 2018: BARD1 Life Sciences Limited (ASX:BD1), a biotechnology company developing non-invasive cancer diagnostics, is pleased to release a new investor presentation providing an update on the Company's strategy and progress.

The presentation summarises:

- Investment highlights and corporate strategy
- BARD1 biomarker platform and progress on development of BARD1-Ovarian test
- Diagnostics commercialisation strategy
- Achievements and expected news flow

A copy of the investor presentation follows.

- ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg
Chairman
E peter@bard1.com

Dr Learne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1's proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The development pipeline includes two BARD1 autoantibody tests in development for early detection of lung and ovarian cancers, and a cancer vaccine project at research-stage for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients' lives. For more information on BARD1, see www.bard1.com.



BARD1

LIFE SCIENCES LIMITED

Early cancer detection to save lives

COMPANY UPDATE

September 2018

Forward Looking Statements

This presentation has been prepared by BARD1 Life Sciences Limited (“BARD1” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in BARD1, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of BARD1 and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. BARD1 is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of BARD1 securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of BARD1 its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and BARD1 does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

This presentation contains certain forward looking statements that are based on the Company’s management beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of BARD1 to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which BARD1 will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, BARD1 and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

BARD1 Life Sciences

Medtech company focused on developing and commercialising non-invasive diagnostics for early detection of cancer to save lives

FINANCIAL INFORMATION		TOP SHAREHOLDERS (@14/9/18)		
Ticker	ASX:BD1	Irmgard Irminger-Finger	108,252,420	13.06%
Share Price (@14/9/18)	A\$0.011	Tony Walker	88,501,626	10.68%
Ordinary Shares	828.66m	CS Fourth Nominees	40,240,000	4.86%
Market Capitalisation (@14/9/18)	A\$9.12m	Peter Gunzburg	29,835,004	3.60%
52w H/L Range	A\$0.035-0.006	Universite de Geneve	12,500,000	1.51%
Cash (@30/6/18)	A\$1.45m	Top 20 Holders	368,828,923	44.51%
Average Daily Volume (3mo)	2.02m	TOTAL	828,662,398	100.00%

SHARE PRICE PERFORMANCE



Investment Highlights


- BARD1-Ovarian test demonstrates **excellent diagnostic accuracy** for detection of ovarian cancer – AUC 0.95 “excellent” on diagnostic scale
- **Targeting unmet needs** in burgeoning US\$101B global cancer diagnostics market
- Focus on commercialising BARD1-Ovarian as a **screening test** to detect ovarian cancer early – for prescription order and govt screening programs
- New study shows **higher accuracy in high-risk women** with family history of breast/ovarian cancer or carrying *BRCA1/2* mutations
- **Clinical studies** expected to commence in 2019 and launch by 2021
- **Pipeline** includes BARD1-Lung for world’s deadliest cancer
- Exploring multiple **partnering and corporate opportunities** to deliver shareholder value
- Value-adding milestones and **news flow expected in near-term**

Corporate Strategy

- Focused on value creation through disciplined, cost-effective development of BARD1's proprietary biomarker technology and diagnostic method
- Lean and efficient – low-dilutive approach to funding
- Major effort concentrated on development of lead diagnostic BARD1-Ovarian to achieve first sales, early revenues and cashflow positive
- Expand product pipeline to BARD-Lung and others cancers
- Board intends to pursue range of corporate and financial opportunities created by recent success of BARD1-Ovarian
- Pursuing accelerated commercialisation options to optimise shareholder value – open-minded and agnostic about how this can occur
- Realising best corporate/financial opportunities and capturing maximum value will be underpinned by consolidation of product development in Australia
- Active promotion of BARD1 Life Sciences and its technology as compelling, good value propositions for global industry partners and investors


Behind BARD1's diagnostic success

- Proprietary tumour marker platform and diagnostic approach
- BARD1 blood tests measure autoantibodies to BARD1 proteins and use an algorithm to give a cancer score
- Autoantibodies indicate the body's early immune response to cancer, present in early stages before symptoms appear
- Existing blood tests often detect tumour-associated antigens, high in late stages after symptoms appear
- Targeting unmet need for early detection of cancer
- Early detection enables earlier treatment, improves patient outcomes, save lives and reduces healthcare costs




Proprietary BARD1 tumour marker platform

- Normal cells express **BARD1 protein** that functions as a *tumour suppressor* to prevent cancer
- Cancer cells express variant **BARD1 isoforms** that drive *tumour formation* and are correlated with cancer progression and poor prognosis
- BARD1 isoforms are immunogenic and induce **BARD1 autoantibodies** reflecting the early *immune response to cancer*



- **BARD1 platform** has potential applications across multiple cancers including ovarian, breast, lung, colorectal and prostate cancers
- **Strong IP** protecting biomarkers, methods and use


Focused on unmet needs in Global Cancer Diagnostics Market of US\$101b¹



Ovarian Cancer continues to devastate

- Ovarian Cancer is the **leading cause of gynecological cancer deaths**
 - World: 239K new cases & 152K deaths pa
 - US: 22,440 new cases & 14,080 deaths pa
- **Risk factors** include aged 55-64 years, family history, and BRCA1/2 mutations
- **Low overall 5-year survival** of 46% since 61% diagnosed at late-stage
- **Early-detection saves lives** increasing survival to over 90%
- **No existing blood test** for early detection

Major unmet medical need for accurate, reliable and affordable blood test for early detection of ovarian cancer



Source: www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html

BARD1-Ovarian changes the landscape

Blood test in development for early detection of ovarian cancer

- **Measures** BARD1 autoantibodies and CA125 in the blood to give an ovarian cancer score
- **7 case-control studies** showing excellent diagnostic accuracy of AUC 0.95 for early detection of ovarian cancer across all stages
- **Industry leading results in average-risk women** with addition of CA-125 biomarker achieving 88% sensitivity & 93% specificity
- New study shows **higher accuracy in high-risk women** with family history of breast/ovarian cancer or carrying *BRCA1/2* mutations achieving 89% sensitivity & 97% specificity

Study	n (cancer:normal)	Model AUC	Test AUC	Sensitivity	Specificity
OC-CA125	400 (200:200)	0.98	0.95	88%	93%
OC-R001	261 (127:134)	0.99	0.97	89%	97%


AUC is the accuracy of the test; Sensitivity is the % of people with cancer that correctly test positive; Specificity is the % people without cancer that correctly test negative.

- Assay development by Thermo Fisher underway to transfer test to **Luminex® instrumentation**
- Clinical studies expected to commence 2019 to evaluate clinical performance as a **screening test for early detection of ovarian cancer in high-risk asymptomatic women**
- Potential to **detect ovarian cancer early, save women's lives and avoid unnecessary surgery**

BARD1 Key Milestones

CY	2018		2019				2020	2021
	Q3	Q4	Q1	Q2	Q3	Q4		
BARD1 <i>Ovarian</i>	Assay Dev				Clinical Validation		Launch	
BARD1 <i>Lung</i>			Assay Dev					
Research	R&D to advance other Dx for early cancer detection							
	IRH cancer vaccine research							
Commercial	BD and partnerships							
			New patents & publications					

Commercialisation Strategy



Leadership Team



PETER GUNZBURG BCom | Chairman

Public company director, stockbroker & technology investor, with 20+ years corporate advisory, capital raising, transaction & business management experience. Currently Chair of the Institute for Respiratory Health at UWA. Previously Director of Resolute Ltd, Australian Stock Exchange Ltd, Eyres Reed Ltd, CIBC World Markets Australia Ltd and Fleetwood Corporation Ltd.



DR IRMGARD IRMINGER-FINGER PD PhD | Executive Director & Chief Scientific Officer

Founder and co-inventor of BARD1 and its technology, European Woman Entrepreneur Award finalist 2014, and internationally recognised expert in tumour biology with over 100 publications, several patents, and multiple international collaborations and keynote conference presentations. Currently Privat Dozent at UNIGE and Adjunct Prof at UWA. Former Executive Director and founder of BARD1AG SA.



BRETT MONTGOMERY | Non-Executive Director

Public company director with extensive experience in leadership, mining company management, corporate governance and risk management. Currently Non-Executive Director of Tanami Gold NL. Previously Managing Director Kalimantan Gold NL, and Director of Magnum Gas and Power Ltd, Grants Patch Mining Ltd and EZA Corporation Ltd.



DR LEEARNE HINCH BVMS MBA | Chief Executive Officer

Accomplished public company CEO and biotechnology consultant with extensive leadership, strategy, fundraising, operational, business development and commercial experience across drugs, devices, diagnostics and animal health. Currently MD of commercialisation advisory Ingeneus Solutions Pty Ltd and former CEO Eustralis Pharmaceuticals Ltd, CEO Immuron Ltd, COO OBI Ltd, GM Holista CollTech Ltd, and CMO Chemeq Ltd.

Peer Valuations | BD1 has significant growth potential

<h2>Ovarian Cancer</h2>	 <p>NASDAQ:VRML US\$40.7m FDA-cleared IVDs OVA1® & Overa® for risk assessment of ovarian cancer with up to 92% sens & 69% spec.</p>	 <p>ASX:BD1 A\$9.1m Development-stage blood test for early detection of ovarian cancer with over 88% sens & 93% spec.</p>	
<h2>Lung Cancer</h2>	 <p>AIM:ONC.L £81.0 Marketed LDT 2009 & CE-IVD 2017 <i>EarlyCDT®</i>-Lung with 41% sens & 93% spec. Jan-18 license with Genostics for China 8-12.5% royalties + £10m equity investment @49% premium. May-18 launch <i>EarlyCDT</i>-Liver.</p>	 <p>ASX:BD1 A\$9.1m Research-stage blood test for early detection of lung cancer with up to 80% sens & 77% spec.</p>	
<h2>Other Cancers</h2>	 <p>FRA:ECX €50.8 FDA-approved & CE-IVD mark Epi proColon® for detection of colorectal cancer in US, EU & China. Jul-17 failed takeover offer by Summit Hero Holding for shares @49.2% premium to 3mo VWAP.</p>	 <p>ASX:SDX A\$22.5m Marketed Class 1 IVD for detection of hTERT in urothelial cells (bladder cancer) IN US, EU & AU.</p>	 <p>ASX:RHY A\$14.6m Development-stage ColoSTAT™ blood test for early detection of colorectal cancer.</p>

Significant Achievements 2018

Date	Announcements
9/1/18	✓ OC-400 results showing 82% sensitivity and 79% specificity for detection of ovarian cancer
2/2/18	✓ JP Divisional Patent granted providing broader protection for lung & colorectal cancer
6/3/18	✓ OC-400V results showing 89% sensitivity and 82% specificity in independent test set
21/3/18	✓ IL Patent granted covering BARD1-Lung
22/3/18	✓ Capital Raising of \$1.3m to institutional and professional investors
18/5/18	✓ Contract Development Agreement signed with TF to transfer research assay to Luminex® instrumentation
19/6/18	✓ OC-125 results with addition of CA125 showing 88% sensitivity and 93% specificity in average-risk women
12/7/18	✓ US Patent granted covering BARD1-Ovarian
6/9/18	✓ OC-R001 results showing 89% sensitivity and 97% specificity in high-risk women

Expected news flow in next 12 months

BARD1-Ovarian

- Complete Assay Development and technical validation on Luminex® instrumentation
- Commence clinical study for early detection of ovarian cancer


Pipeline

- Initiate further product development for BARD1-Lung
- Results from BARD1-Vaccine mouse studies
- Results from research studies for other cancers

Commercial

- Progress corporate and partnering discussions
- Additional patents and publications
- Strengthen Board and management

Investment Summary



BARD1

Contacts

BARD1 Life Sciences Ltd

Ground, Tempo Building, 431 Roberts Rd
Subiaco WA 6008 Australia


P +61 8 9381 9550 | **E** info@bard1.com | **W** www.bard1.com

Peter Gunzburg | Chairman
E peter@bard1.com

Dr Learne Hinch | CEO
E learne@bard1.com
M 0400414418

Lung Cancer remains the biggest cancer killer

- Lung Cancer is the **leading cause of cancer deaths** worldwide
 - World: 1.82m new cases & 1.59m deaths pa
 - US: 222,500 new cases & 155,870 deaths pa
- **Smoking** is major risk factor in 85% cases
- **Poor overall 5-year survival** of 18% since 80% diagnosed at late-stage
- **Early-detection saves lives** increasing survival to over 49%
- **Annual CT screening** recommended in high-risk asymptomatic adults aged 55-80 years with >30 pack-year smoking history (USPSTF 2014)



Source: <https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging/survival-rates.html>

Unmet need for accurate, reliable and affordable blood test for early detection

BARD1-Lung test

Blood test in development for early detection of lung cancer

- **Measures** BARD1 autoantibodies in the blood to give a lung cancer score
- **2 case-control studies** showing high accuracy for early detection of lung cancer with up to **80% sensitivity and 77% specificity**, and promising results for gender-specific algorithms with model AUC=0.91 in males and AUC-0.89 in females

Study	n (cancer:normal)	Model AUC	Test AUC	Sensitivity	Specificity
LC-POC	187 (94:93)	0.96	0.86	80%	77%
LC-600	628 (395:233)	0.85	0.80	80%	68%

AUC is the accuracy of the test; Sensitivity is the % of people with cancer that correctly test positive; Specificity is the % people without cancer that correctly test negative.

- **Publication** of POC results and diagnostic method in peer-reviewed journal *PloS ONE*
- **Assay development** planned for early 2019 to optimise and analytically validate test on Luminex[®] instrumentation using additional biomarkers & gender-specific algorithms
- **Clinical studies** required to evaluate clinical performance for intended use as a screening test for early detection of lung cancer in high-risk asymptomatic individuals
- Potential to **detect lung cancer early, save lives and reduce healthcare costs**

BARD1's Intellectual Property Portfolio

- 5 patent families covering various BARD1 DNA & protein sequences, methods of diagnosis & treatment, and use in multiple cancers

Patent Family 5	Title	Granted 9	Pending 19	Expiry
PCT/FR01/02731	Truncated BARD1 protein and its diagnostic and therapeutic uses	US, JP		2021
PCT/IB2011/053635	BARD1 isoforms in lung and colorectal cancer and use thereof	US, JP, JP (div), IL, CN, AU	US, CN (divisionals), EP, CA, BR, SG, HK	2031*
PCT/IB2011/054194	Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof	US	EP	2031*
PCT/EP2014/073834	Lung Cancer Diagnosis		US, EP, CA, JP, IL, CN, AU, SG, KR, HK	2034*
EP14002398.7	Novel non-coding RNA, cancer target and compounds for cancer treatment		US	2035*

*Plus any extension of term in the US due to prosecution delay